Published in Nucleic Acids Res on April 15, 1998
Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents. Nucleic Acids Res (2009) 2.22
Therapeutic potential of antisense oligonucleotides as modulators of alternative splicing. J Clin Invest (2003) 1.89
Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice. Nucleic Acids Res (2014) 1.18
Enhanced delivery of antisense oligonucleotides with fluorophore-conjugated PAMAM dendrimers. Nucleic Acids Res (2000) 1.16
TCP1 complex proteins interact with phosphorothioate oligonucleotides and can co-localize in oligonucleotide-induced nuclear bodies in mammalian cells. Nucleic Acids Res (2014) 1.02
Histidylated oligolysines increase the transmembrane passage and the biological activity of antisense oligonucleotides. Nucleic Acids Res (2000) 0.95
Identification and characterization of intracellular proteins that bind oligonucleotides with phosphorothioate linkages. Nucleic Acids Res (2015) 0.95
Sequence-dependent cytotoxicity of second-generation oligonucleotides. Nucleic Acids Res (2004) 0.95
Bioconjugation of oligonucleotides for treating liver fibrosis. Oligonucleotides (2007) 0.88
Poly(propylacrylic acid) enhances cationic lipid-mediated delivery of antisense oligonucleotides. Biomacromolecules (2006) 0.87
LNA-based oligonucleotide electrotransfer for miRNA inhibition. Mol Ther (2012) 0.84
Translation of stable hepadnaviral mRNA cleavage fragments induced by the action of phosphorothioate-modified antisense oligodeoxynucleotides. Nucleic Acids Res (2005) 0.84
Efficient cationic lipid-mediated delivery of antisense oligonucleotides into eukaryotic cells: down-regulation of the corticotropin-releasing factor receptor. Nucleic Acids Res (2001) 0.84
Molecular therapy in ocular wound healing. Br J Ophthalmol (1999) 0.84
Nanoplasmonic gene regulation. Curr Opin Chem Biol (2010) 0.83
Subcellular trafficking of antisense oligonucleotides and down-regulation of bcl-2 gene expression in human melanoma cells using a fusogenic liposome delivery system. Nucleic Acids Res (2002) 0.78
Sub-cellular temporal and spatial distribution of electrotransferred LNA/DNA oligomer. J RNAi Gene Silencing (2013) 0.77
Liposomal Spherical Nucleic Acids for Regulating Long Noncoding RNAs in the Nucleus. Small (2016) 0.75
A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci U S A (1995) 18.16
Cellular and molecular barriers to gene transfer by a cationic lipid. J Biol Chem (1995) 4.39
Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol Pharmacol (1992) 3.42
Characterization of oligonucleotide transport into living cells. Proc Natl Acad Sci U S A (1989) 3.27
Gene inhibition using antisense oligodeoxynucleotides. Nature (1994) 3.26
Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc Natl Acad Sci U S A (1991) 2.76
Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature (1992) 2.73
Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms. J Biol Chem (1991) 2.65
Intracellular distribution of microinjected antisense oligonucleotides. Proc Natl Acad Sci U S A (1991) 2.22
Mechanism of oligonucleotide release from cationic liposomes. Proc Natl Acad Sci U S A (1996) 2.19
Inhibition of protein kinase C-alpha expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters. J Biol Chem (1994) 2.00
Selective inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotides. J Biol Chem (1992) 1.99
Mechanism of oligonucleotide uptake by cells: involvement of specific receptors? Proc Natl Acad Sci U S A (1989) 1.97
Progress in antisense oligonucleotide therapeutics. Annu Rev Pharmacol Toxicol (1996) 1.60
Design, synthesis, and characterization of a cationic peptide that binds to nucleic acids and permeabilizes bilayers. Biochemistry (1997) 1.56
Delivery of plasmid DNA into mammalian cell lines using pH-sensitive liposomes: comparison with cationic liposomes. Pharm Res (1992) 1.56
Rapid nuclear accumulation of injected oligodeoxyribonucleotides. New Biol (1990) 1.45
Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides. J Clin Invest (1995) 1.44
A serum-resistant cytofectin for cellular delivery of antisense oligodeoxynucleotides and plasmid DNA. Proc Natl Acad Sci U S A (1996) 1.38
Specific inhibition of hepatitis B viral gene expression in vitro by targeted antisense oligonucleotides. J Biol Chem (1992) 1.36
Regulation of in vitro gene expression using antisense oligonucleotides or antisense expression plasmids transfected using starburst PAMAM dendrimers. Nucleic Acids Res (1996) 1.32
In vivo fate of phosphorothioate antisense oligodeoxynucleotides: predominant uptake by scavenger receptors on endothelial liver cells. Nucleic Acids Res (1997) 1.28
Inhibition of protein kinase C-alpha expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides. Proc Natl Acad Sci U S A (1994) 1.25
Cellular distribution of phosphorothioate oligodeoxynucleotides in normal rodent tissues. Lab Invest (1997) 1.25
Intracellular distribution and mechanism of delivery of oligonucleotides mediated by cationic lipids. Pharm Res (1996) 1.23
Biological activity of oligonucleotide-poly(L-lysine) conjugates: mechanism of cell uptake. Bioconjug Chem (1991) 1.22
Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. J Pharmacol Exp Ther (1993) 1.22
Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycol. Proc Natl Acad Sci U S A (1995) 1.21
Comparison of cellular binding and uptake of antisense phosphodiester, phosphorothioate, and mixed phosphorothioate and methylphosphonate oligonucleotides. Antisense Res Dev (1993) 1.19
Modification of antisense phosphodiester oligodeoxynucleotides by a 5' cholesteryl moiety increases cellular association and improves efficacy. Proc Natl Acad Sci U S A (1993) 1.17
Inhibition of leukemia cell proliferation by receptor-mediated uptake of c-myb antisense oligodeoxynucleotides. Proc Natl Acad Sci U S A (1992) 1.14
Inhibition of growth of human tumor cell lines in nude mice by an antisense of oligonucleotide inhibitor of protein kinase C-alpha expression. Cancer Res (1996) 1.12
Intracellular availability of unmodified, phosphorothioated and liposomally encapsulated oligodeoxynucleotides for antisense activity. Nucleic Acids Res (1992) 1.11
Improved biological activity of antisense oligonucleotides conjugated to a fusogenic peptide. Nucleic Acids Res (1994) 1.10
Inhibition of expression of the multidrug resistance-associated P-glycoprotein of by phosphorothioate and 5' cholesterol-conjugated phosphorothioate antisense oligonucleotides. Mol Pharmacol (1996) 1.09
Analysis of oligonucleotide binding, internalization, and intracellular trafficking utilizing a novel radiolabeled crosslinker. Antisense Res Dev (1992) 1.02
Overcoming multidrug resistance in human tumor cells using free and liposomally encapsulated antisense oligodeoxynucleotides. Biochem Biophys Res Commun (1993) 1.00
The uptake kinetics of chimeric oligodeoxynucleotide analogues in human leukaemia MOLT-4 cells. Anticancer Drug Des (1992) 0.96
Electroporation enhances c-myc antisense oligodeoxynucleotide efficacy. Nucleic Acids Res (1993) 0.94
Characterization of complexes of oligonucleotides with polyamidoamine starburst dendrimers and effects on intracellular delivery. J Pharm Sci (1997) 0.94
Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-alpha phosphorothioate oligodeoxynucleotide. Mol Pharmacol (1996) 0.91
The kinetic aspects of intracellular fluorescence labeling with TMA-DPH support the maturation model for endocytosis in L929 cells. J Cell Biol (1994) 0.87
Evaluation of adjuvants that enhance the effectiveness of antisense oligodeoxynucleotides. Pharm Res (1996) 0.86
The therapeutic potential of antisense oligonucleotides. Bioessays (1995) 0.86
Cellular uptake mechanism for oligonucleotides: involvement of endocytosis in the uptake of phosphodiester oligonucleotides by a human colorectal adenocarcinoma cell line, HCT-15. J Pharmacol Exp Ther (1996) 0.85
Enhanced biological activity of antisense oligonucleotides complexed with glycosylated poly-L-lysine. Mol Pharmacol (1996) 0.84
Novel polyaminolipids enhance the cellular uptake of oligonucleotides. J Biol Chem (1995) 0.84
Improved cellular delivery of antisense oligonucleotides using transferrin receptor antibody-oligonucleotide conjugates. Pharm Res (1995) 0.83
Inhibition of cell adhesion to plastic substratum by phosphorothioate oligonucleotide. Exp Cell Res (1992) 0.82
Enhanced delivery of synthetic oligonucleotides to human leukaemic cells by liposomes and immunoliposomes. Leuk Res (1997) 0.82
Specific suppression of human tumor necrosis factor-alpha synthesis by antisense oligodeoxynucleotides. Antisense Nucleic Acid Drug Dev (1996) 0.81
Biosynthesis in vitro of fucose-containing glycosphingolipids in human neuroblastoma IMR-32 cells. Proc Natl Acad Sci U S A (1978) 0.80
Functions and structures of ribonuclease H enzymes. Subcell Biochem (1995) 0.80
Binding of oligonucleotides to cell membranes at acidic pH. Biochem Biophys Res Commun (1991) 0.79
Delivery of oligoribonucleotides to human hepatoma cells using cationic lipid particles conjugated to ferric protoporphyrin IX (heme). Antisense Nucleic Acid Drug Dev (1997) 0.77
Developing oligonucleotide therapeutics for human leukemia. Anticancer Drug Des (1997) 0.77
The CATH database: an extended protein family resource for structural and functional genomics. Nucleic Acids Res (2003) 8.36
Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat Cell Biol (1999) 4.11
Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc Natl Acad Sci U S A (2007) 3.07
Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms. J Biol Chem (1991) 2.65
Induction of endogenous Bcl-xS through the control of Bcl-x pre-mRNA splicing by antisense oligonucleotides. Nat Biotechnol (1999) 2.27
Modification of splicing in the dystrophin gene in cultured Mdx muscle cells by antisense oligoribonucleotides. Hum Mol Genet (1998) 2.07
Dissected nucleus-independent chemical shift analysis of pi-aromaticity and antiaromaticity. Org Lett (2001) 2.01
Inhibition of protein kinase C-alpha expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters. J Biol Chem (1994) 2.00
Expression of human group II PLA2 in transgenic mice results in epidermal hyperplasia in the absence of inflammatory infiltrate. J Clin Invest (1996) 1.76
Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-alpha expression. J Biol Chem (1999) 1.76
Separation of multiple isomers of inositol phosphates formed in GH3 cells. Biochem J (1987) 1.73
Pharmacokinetic properties of 2'-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats. J Pharmacol Exp Ther (2001) 1.73
Nuclear antisense effects of neutral, anionic and cationic oligonucleotide analogs. Nucleic Acids Res (2001) 1.67
Crystal structure and improved antisense properties of 2'-O-(2-methoxyethyl)-RNA. Nat Struct Biol (1999) 1.65
Cationic lipid is not required for uptake and selective inhibitory activity of ICAM-1 phosphorothioate antisense oligonucleotides in keratinocytes. J Invest Dermatol (1994) 1.63
Progress in antisense oligonucleotide therapeutics. Annu Rev Pharmacol Toxicol (1996) 1.60
Pseudo--half-knot formation with RNA. Science (1992) 1.58
ETV6/AML1 fusion by FISH in adult acute lymphoblastic leukemia. Leukemia (2002) 1.54
Detection of alkali metal ions in DNA crystals using state-of-the-art X-ray diffraction experiments. Nucleic Acids Res (2001) 1.49
Taxonomy and phylogeny of industrial solvent-producing clostridia. Int J Syst Bacteriol (1995) 1.48
Impacts of urbanisation on the lifestyle and on the prevalence of diabetes in native Asian Indian population. Diabetes Res Clin Pract (1999) 1.48
The Jun kinase 2 isoform is preferentially required for epidermal growth factor-induced transformation of human A549 lung carcinoma cells. Mol Cell Biol (1999) 1.47
cyt gene of adenoviruses 2 and 5 is an oncogene for transforming function in early region E1B and encodes the E1B 19,000-molecular-weight polypeptide. J Virol (1984) 1.45
PDGF-induced activation of phospholipase C is not required for induction of DNA synthesis. Science (1990) 1.44
Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis. Nat Biotechnol (2000) 1.43
Inositol 1,3,4,5-tetrakisphosphate induces Ca2+ sequestration in rat liver cells. Science (1988) 1.42
X-ray crystallographic analysis of the hydration of A- and B-form DNA at atomic resolution. Biopolymers (1998) 1.40
Regulation and targeting of antiapoptotic XIAP in acute myeloid leukemia. Leukemia (2003) 1.39
Role of the intercellular adhesion molecule-1(ICAM-1) in endotoxin-induced pneumonia evaluated using ICAM-1 antisense oligonucleotides, anti-ICAM-1 monoclonal antibodies, and ICAM-1 mutant mice. J Clin Invest (1996) 1.38
Pharmacokinetic properties of several novel oligonucleotide analogs in mice. J Pharmacol Exp Ther (1996) 1.38
5' phospholipid phosphatase SHIP-2 causes protein kinase B inactivation and cell cycle arrest in glioblastoma cells. Mol Cell Biol (2000) 1.31
Inhibition of c-Jun N-terminal kinase 2 expression suppresses growth and induces apoptosis of human tumor cells in a p53-dependent manner. Mol Cell Biol (2000) 1.29
Serine/threonine protein phosphatase 5 (PP5) participates in the regulation of glucocorticoid receptor nucleocytoplasmic shuttling. BMC Cell Biol (2001) 1.28
In vivo fate of phosphorothioate antisense oligodeoxynucleotides: predominant uptake by scavenger receptors on endothelial liver cells. Nucleic Acids Res (1997) 1.28
A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology (1998) 1.28
Chemically modified oligonucleotides exhibit decreased immune stimulation in mice. J Pharmacol Exp Ther (2000) 1.28
Serine/threonine protein phosphatase type 5 acts upstream of p53 to regulate the induction of p21(WAF1/Cip1) and mediate growth arrest. J Biol Chem (1998) 1.27
Limitations of biopsy Gleason grade: implications for counseling patients with biopsy Gleason score 6 prostate cancer. J Urol (2004) 1.27
Activated Ras prevents downregulation of Bcl-X(L) triggered by detachment from the extracellular matrix. A mechanism of Ras-induced resistance to anoikis in intestinal epithelial cells. J Cell Biol (2000) 1.27
Suppression of vascular endothelial growth factor-mediated endothelial cell protection by survivin targeting. Am J Pathol (2001) 1.27
Ser/Thr protein phosphatase type 5 (PP5) is a negative regulator of glucocorticoid receptor-mediated growth arrest. Biochemistry (1999) 1.26
Nucleocytoplasmic shuttling: a novel in vivo property of antisense phosphorothioate oligodeoxynucleotides. Nucleic Acids Res (2000) 1.25
Cellular distribution of phosphorothioate oligodeoxynucleotides in normal rodent tissues. Lab Invest (1997) 1.25
Inhibition of PDK-1 activity causes a reduction in cell proliferation and survival. Curr Biol (2000) 1.22
Purification and characterization of the purE, purK, and purC gene products: identification of a previously unrecognized energy requirement in the purine biosynthetic pathway. Biochemistry (1992) 1.18
Mapping the 5' ends, 3' ends, and splice sites of mRNAs from the early E3 transcription unit of adenovirus 5. Virology (1985) 1.18
Novel antisense oligonucleotides targeting TGF-beta inhibit in vivo scarring and improve surgical outcome. Gene Ther (2003) 1.17
PKC-epsilon is required for mechano-sensitive activation of ERK1/2 in endothelial cells. J Biol Chem (1997) 1.17
Nonhistone protein BA is a glutathione S-transferase localized to interchromatinic regions of the cell nucleus. J Cell Biol (1986) 1.12
ADAM17 but not ADAM10 mediates tumor necrosis factor-alpha and L-selectin shedding from leukocyte membranes. Antisense Nucleic Acid Drug Dev (2001) 1.11
The kinetics of phosphoinositide hydrolysis in rat basophilic leukemia (RBL-2H3) cells varies with the type of IgE receptor cross-linking agent used. J Biol Chem (1987) 1.11
Pharmacokinetics and pharmacodynamics of an antisense phosphorothioate oligonucleotide targeting Fas mRNA in mice. J Pharmacol Exp Ther (2001) 1.11
c-Jun N-terminal kinase is essential for growth of human T98G glioblastoma cells. J Biol Chem (2000) 1.10
Serine/threonine protein phosphatase type 1gamma1 is required for the completion of cytokinesis in human A549 lung carcinoma cells. J Biol Chem (2000) 1.10
Enhanced metastatic ability of TNF-alpha-treated malignant melanoma cells is reduced by intercellular adhesion molecule-1 (ICAM-1, CD54) antisense oligonucleotides. Exp Cell Res (1994) 1.09
Inhibition of expression of the multidrug resistance-associated P-glycoprotein of by phosphorothioate and 5' cholesterol-conjugated phosphorothioate antisense oligonucleotides. Mol Pharmacol (1996) 1.09
A reverse perfusion pattern during Technetium-99m stress myocardial perfusion imaging does not predict flow limiting coronary artery disease. Int J Cardiovasc Imaging (2004) 1.06
Identification of an estrogen-inducible phosphatase (PP5) that converts MCF-7 human breast carcinoma cells into an estrogen-independent phenotype when expressed constitutively. J Biol Chem (2001) 1.05
Blocking of heart allograft rejection by intercellular adhesion molecule-1 antisense oligonucleotides alone or in combination with other immunosuppressive modalities. J Immunol (1994) 1.05
Structural properties of DNA:RNA duplexes containing 2'-O-methyl and 2'-S-methyl substitutions: a molecular dynamics investigation. Nucleic Acids Res (1999) 1.05
Inhibition of (cytosine C5)-methyltransferase by oligonucleotides containing flexible (cyclopentane) and conformationally constrained (bicyclo[3.1.0]hexane) abasic sites. Nucleosides Nucleotides Nucleic Acids (2001) 1.05
Inhibition of Bcl-xL expression sensitizes normal human keratinocytes and epithelial cells to apoptotic stimuli. Oncogene (1999) 1.04
Phosphorothioate oligodeoxynucleotides distribute similarly in class A scavenger receptor knockout and wild-type mice. J Pharmacol Exp Ther (2000) 1.04
A constitutive cytoprotective pathway protects endothelial cells from lipopolysaccharide-induced apoptosis. J Biol Chem (2001) 1.04
Second-generation antisense oligonucleotides: structure-activity relationships and the design of improved signal-transduction inhibitors. Biochem Soc Trans (1996) 1.03
The role of antiapoptotic Bcl-2 family members in endothelial apoptosis elucidated with antisense oligonucleotides. J Biol Chem (1999) 1.02
Formation of inositol 1,4,5-trisphosphate and inositol 1,3,4-trisphosphate from inositol 1,3,4,5-tetrakisphosphate and their pathways of degradation in RBL-2H3 cells. J Biol Chem (1988) 1.02
Immune stimulation--a class effect of phosphorothioate oligodeoxynucleotides in rodents. Anticancer Drug Des (1997) 1.01
Mechanism of phorbol ester inhibition of histamine-induced IP3 formation in cultured airway smooth muscle. Am J Physiol (1989) 1.01
Islet-activating protein inhibits leukotriene D4- and leukotriene C4- but not bradykinin- or calcium ionophore-induced prostacyclin synthesis in bovine endothelial cells. Proc Natl Acad Sci U S A (1986) 1.00
p27Kip1 is required for PTEN-induced G1 growth arrest. Cancer Res (2001) 0.99
Reduction of expression of the multidrug resistance protein (MRP) in human tumor cells by antisense phosphorothioate oligonucleotides. Biochem Pharmacol (1996) 0.98
Medical education in India, with special reference to community medicine. Br J Med Educ (1968) 0.98
Conjugation of oligonucleotides via an electrophilic tether: N-chloroacetamidohexyl phosphoramidite reagent. Bioorg Med Chem Lett (1998) 0.98
Phosphorothioate antisense oligonucleotides induce the formation of nuclear bodies. Mol Biol Cell (1998) 0.96
Fully modified 2' MOE oligonucleotides redirect polyadenylation. Nucleic Acids Res (2001) 0.96
Modulation of plasma protein binding and in vivo liver cell uptake of phosphorothioate oligodeoxynucleotides by cholesterol conjugation. Nucleic Acids Res (2000) 0.95
Inhibition of survivin expression suppresses the growth of aggressive non-Hodgkin's lymphoma. Leukemia (2004) 0.95
Deletion of individual exons and induction of soluble murine interleukin-5 receptor-alpha chain expression through antisense oligonucleotide-mediated redirection of pre-mRNA splicing. Mol Pharmacol (2000) 0.93
The acenes: is there a relationship between aromatic stabilization and reactivity? Org Lett (2001) 0.93
Monosomy 20 as a pointer to dicentric (9;20) in acute lymphoblastic leukemia. Leukemia (2000) 0.93
Altered mRNA splicing and inhibition of human E-selectin expression by an antisense oligonucleotide in human umbilical vein endothelial cells. J Biol Chem (1996) 0.93
Structural origins of the exonuclease resistance of a zwitterionic RNA. Proc Natl Acad Sci U S A (1999) 0.93
Antisense down-regulation of thymidylate synthase to suppress growth and enhance cytotoxicity of 5-FUdR, 5-FU and Tomudex in HeLa cells. Br J Pharmacol (1999) 0.93
Cytosolic delivery of antisense oligonucleotides by listeriolysin O-containing liposomes. Gene Ther (2003) 0.92
Accuracy of single-photon emission computed tomography in differentiating frontotemporal dementia from Alzheimer's disease. J Neurol Neurosurg Psychiatry (2006) 0.91
Antisense oligonucleotides as inhibitors of signal transduction: development from research tools to therapeutic agents. Biochem Soc Trans (1996) 0.91
Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-alpha phosphorothioate oligodeoxynucleotide. Mol Pharmacol (1996) 0.91
In vitro and in vivo pharmacologic activities of antisense oligonucleotides. Anticancer Drug Des (1991) 0.90
Novel chemically modified oligonucleotides provide potent inhibition of P-glycoprotein expression. J Pharmacol Exp Ther (1998) 0.90
Sensible use of antisense: how to use oligonucleotides as research tools. Trends Pharmacol Sci (2000) 0.90
Up-regulation of the Pit-2 phosphate transporter/retrovirus receptor by protein kinase C epsilon. J Biol Chem (1999) 0.90
Human melanoma metastasis is inhibited following ex vivo treatment with an antisense oligonucleotide to protein kinase C-alpha. Cancer Lett (1998) 0.89